Matthew Mosconi is associate professor of clinical child psychology and of the Life Span Institute at the University of Kansas, and director of the Kansas Center for Autism Research and Training.
Matthew Mosconi
Associate professor
University of Kansas
From this contributor
New tool may speed up drugs to ease need for sameness in autism
Using a new task to test resistance to change in autism, we are developing leads for treatments for this troublesome trait.
New tool may speed up drugs to ease need for sameness in autism
By
Matthew Mosconi, Michael Ragozzino
13 March 2018 | 7 min read
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
By
Ashley Juavinett
30 March 2026 | 8 min read
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
By
Dalmeet Singh Chawla
27 March 2026 | 5 min read
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
By
Claudia López Lloreda
26 March 2026 | 4 min read